SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice

Here, the authors characterize a SARS-CoV-2 subunit vaccine candidate that contains full-length spike protein stabilized in its prefusion conformation, and show immunogenicity in baboons and protection in mice with Matrix-M adjuvanted vaccine.

Bibliographic Details
Main Authors:	Jing-Hui Tian, Nita Patel, Robert Haupt, Haixia Zhou, Stuart Weston, Holly Hammond, James Logue, Alyse D. Portnoff, James Norton, Mimi Guebre-Xabier, Bin Zhou, Kelsey Jacobson, Sonia Maciejewski, Rafia Khatoon, Malgorzata Wisniewska, Will Moffitt, Stefanie Kluepfel-Stahl, Betty Ekechukwu, James Papin, Sarathi Boddapati, C. Jason Wong, Pedro A. Piedra, Matthew B. Frieman, Michael J. Massare, Louis Fries, Karin Lövgren Bengtsson, Linda Stertman, Larry Ellingsworth, Gregory Glenn, Gale Smith
Format:	Article
Language:	English
Published:	Nature Portfolio 2021-01-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-020-20653-8

Similar Items

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
by: Matthew J. Gorman, et al.
Published: (2021-09-01)

Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine
by: Eddie Underwood, et al.
Published: (2023-12-01)

Safety and efficacy of NVX-CoV2373 Covid-19 vaccine
by: Heath, PT, et al.
Published: (2021)

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
by: Kirsten E. Lyke, et al.
Published: (2023-07-01)

Protein vaccine NVX-CoV2373 elicits functional T cell immunity
by: Pengcheng Zhou
Published: (2022-10-01)

Myopericarditis following both BNT162b2 and NVX-CoV2373
by: Saima Ahmad, et al.
Published: (2022-12-01)

Angioedema‐like eyelid edema following the second NVX‐CoV2373 COVID‐19 vaccination
by: Mari Matsumoto, et al.
Published: (2023-10-01)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
by: Jinal N. Bhiman, et al.
Published: (2023-01-01)

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses
by: Carolyn Rydyznski Moderbacher, et al.
Published: (2022-10-01)

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
by: Lauffenburger, Douglas
Published: (2023)

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines
by: Toback, S, et al.
Published: (2021)

NVX-CoV2373 induces humoral and cellular immune responses that are functionally comparable to vector and mRNA-based vaccines
by: Franz Mai, et al.
Published: (2024-03-01)

NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines
by: Magdalena Mueller-Enz, et al.
Published: (2023-07-01)

Safety and efficacy of the NVX-CoV2373 coronavirus disease 2019 vaccine at completion of the placebo-controlled phase of a randomized controlled trial
by: Heath, PT, et al.
Published: (2022)

Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines
by: Anthony M. Marchese, et al.
Published: (2023-12-01)

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
by: Neil Formica, et al.
Published: (2021-10-01)

Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase
by: Diego Macías Saint-Gerons, et al.
Published: (2023-02-01)

Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyResearch in context
by: Prasad S. Kulkarni, et al.
Published: (2023-03-01)

Cytokine and Chemokine Production in Mice Inoculated with NVX-CoV2373 (Nuvaxovid<sup>®</sup>) in Comparison with Omicron BA.4/5 Bivalent BNT162b2 (Comirnaty<sup>®</sup>)
by: Tetsuo Nakayama, et al.
Published: (2023-11-01)

CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replication in vitro and in vivo.
by: James Logue, et al.
Published: (2023-12-01)

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
by: James Logue, et al.
Published: (2023-02-01)

2373
by: Serena-Kaye Kinley-Cooper, et al.
Published: (2017-09-01)

Inhibition of the IFN-α JAK/STAT Pathway by MERS-CoV and SARS-CoV-1 Proteins in Human Epithelial Cells
by: Yamei Zhang, et al.
Published: (2022-03-01)

Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV
by: Rajat Goyal, et al.
Published: (2022-09-01)

Neuropathogenesis of SARS-CoV-2 infection
by: Shumayila Khan, et al.
Published: (2020-07-01)

Diabetes and coronavirus infections (SARS-CoV, MERS-CoV, and SARS-CoV-2)
by: Azadeh Haghi Navand, et al.
Published: (2020-01-01)

A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV
by: Huan Zhou, et al.
Published: (2021-12-01)

Data mining of coronavirus: SARS-CoV-2, SARS-CoV and MERS-CoV
by: Jung Eun Huh, et al.
Published: (2021-04-01)

SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
by: T.M. Abdelghany, et al.
Published: (2021-03-01)

The Comparison of SARS-CoV-2, SARS-CoV, and MERS-CoV Genome and Spike Protein Variations
by: Choirun Nita Fikriani, et al.
Published: (2021-03-01)

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
by: Yun-yu Zhang, et al.
Published: (2020-08-01)

Computational analysis of SARS-CoV-2, SARS-CoV, and MERS-CoV genome using MEGA
by: Vipan Kumar Sohpal
Published: (2020-09-01)

The emerging SARS-CoV, MERS-CoV, and SARS-CoV-2: An insight into the viruses zoonotic aspects
by: Karima A. Al-Salihi, et al.
Published: (2021-01-01)

Comparison between SARS-CoV and SARS-CoV 2
by: Fang Meng
Published: (2021-01-01)

Autopsy Tool in Unknown Diseases: The Experience with Coronaviruses (SARS-CoV, MERS-CoV, SARS-CoV-2)
by: Francesco Sessa, et al.
Published: (2021-03-01)

An Exploration of Nanoparticle-Based Diagnostic Approaches for Coronaviruses: SARS-CoV-2, SARS-CoV and MERS-CoV
by: Ahmed Al-Hindawi, et al.
Published: (2022-10-01)

Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
by: Qiao Wang, et al.
Published: (2023-03-01)

Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses
by: Zeinab Abdelrahman, et al.
Published: (2020-09-01)

Immune responses in SARS-CoV-2, SARS-CoV, and MERS-CoV infections: A comparative review
by: Soussan Irani
Published: (2022-01-01)

MERS-CoV
by: Beuy Joob, et al.
Published: (2014-09-01)